In the realm of public health and safety, the U.S. Food and Drug Administration (FDA) and the U.S. Department of Justice (DOJ) made significant strides in 2025 through various enforcement actions. These initiatives reflect long-standing enforcement priorities while adapting to new policy objectives from the current administration. This review provides insights into the evolving landscape of FDA regulations, highlights key enforcement activities, and addresses the implications of recent organizational changes at the DOJ and FDA.
Shifting Enforcement Priorities
In 2025, FDA and DOJ enforcement actions focused on critical areas like product quality, safety, and clinical research integrity. An emphasis on patient safety has redefined these enforcement initiatives, aligning them closely with the administration’s public health goals, particularly those articulated by the Make America Healthy Again (MAHA) movement.
For instance, the government launched an aggressive approach to combat misleading direct-to-consumer (DTC) drug advertisements, aiming for enhanced transparency about safety risks. This reflects a commitment to countering overmedicalization and addressing chronic health issues in the nation. The renewed focus on gender-affirming care further illustrates a shift in enforcement strategies, potentially reviving off-label promotion theories in this sensitive context.
The Push Against Overcriminalization
A significant development in regulatory enforcement is Executive Order 14294, issued in May 2025, which seeks to mitigate the criminal prosecution of regulatory offenses. This order emphasizes that criminal enforcement should be a last resort, advocating for civil and administrative measures instead. This directive may notably affect FDA-regulated industries, where strict liability offenses under the Federal Food, Drug, and Cosmetic Act (FDCA) have historically led to criminal charges.
Should this order be implemented effectively, it could reduce the frequency of criminal prosecutions under the FDCA. This shift may encourage the FDA to rely more heavily on civil enforcement mechanisms, such as injunctions and seizures, while prompting DOJ to explore civil enforcement theories like the False Claims Act (FCA).
Workforce Changes and Their Implications
The FDA and DOJ faced substantial workforce reductions in 2025, impacting their enforcement capabilities. An organizational shake-up at the DOJ resulted in the disbanding of the Consumer Protection Branch, which previously oversaw FDCA enforcement matters. This dissolution could lead to inconsistencies in enforcement actions, as remaining DOJ components may not possess the specialized knowledge of FDA regulations.
Moreover, personnel losses at both agencies may hinder inspection capacities and the ability to conduct thorough investigations. The resultant decline in FDA enforcement resources may push DOJ to rely on FCA or other non-FDCA enforcement strategies, potentially leading to less substantive FDA involvement in investigations.
Key Enforcement Activities in 2025
Several notable enforcement actions in 2025 highlight the evolving regulatory landscape. High-profile criminal prosecutions underscored the personal liability of executives in medical device companies, with cases resulting in guilty pleas and significant financial penalties.
For instance, former executives from Magellan Diagnostics were prosecuted for concealing device malfunctions, while a physician faced charges for distributing recalled respiratory devices. These cases illustrate the increasing scrutiny on individual accountability within the FDA regulatory framework.
Gender-Affirming Care Investigations
One of the most consequential enforcement developments in 2025 was the administration’s directive to scrutinize gender-affirming care. The issuance of Executive Order 14187 sought to limit access to such care for minors, prompting investigations into providers and pharmaceutical companies. The DOJ’s civil enforcement actions in this area, including subpoenas issued to healthcare facilities, signal a commitment to monitoring and regulating this sensitive aspect of medical care.
Increased Focus on Drug Advertising
In 2025, the FDA and DOJ intensified their scrutiny of drug advertising, particularly focusing on DTC advertisements. The agencies pursued aggressive enforcement actions against manufacturers and pharmacies, issuing over 125 warning letters for misleading claims. This heightened vigilance indicates a clear shift toward ensuring compliance in promotional practices.
The Role of the False Claims Act
The FCA emerged as a prominent tool for addressing violations of FDA regulations in 2025. Several enforcement actions resolved under the FCA highlighted compliance issues related to FDA-approved products being marketed for unapproved uses. This trend suggests a willingness to pursue enforcement through civil avenues rather than relying solely on criminal prosecutions.
Preparing for Future Enforcement Trends
As the landscape of FDA enforcement continues to evolve, stakeholders should remain vigilant and proactive. Companies must prioritize compliance and quality assurance programs to navigate the complexities of regulatory requirements effectively.
Understanding the implications of organizational changes within the FDA and DOJ is crucial for anticipating how enforcement strategies may shift. While the focus on overcriminalization may reduce certain prosecutions, violations related to product quality and safety will likely remain a priority for regulators.
Key Takeaways
- Evolving Enforcement Landscape: The FDA and DOJ are adapting enforcement strategies to align with new public health priorities, particularly regarding DTC advertising and gender-affirming care.
- Focus on Individual Accountability: Recent prosecutions signal increased scrutiny on personal liability for executives in FDA-regulated industries.
-
Civil Enforcement Tools: The False Claims Act is becoming a favored method for addressing regulatory violations, potentially reducing reliance on criminal prosecutions.
-
Organizational Changes Impact Enforcement: Workforce reductions and structural changes within the FDA and DOJ may affect the consistency and efficiency of enforcement actions.
In conclusion, as we transition into 2026, the FDA and DOJ’s enforcement landscape will likely remain dynamic and multifaceted. Companies must stay informed and ready to adapt to ongoing regulatory changes and enforcement strategies that prioritize public health and safety.
Read more → www.jdsupra.com